Current
31.9×
5-Year Average
32.6×
All-Time High
260.3×
All-Time Low
6.7×
P/FCF Ratio daily chart for AstraZeneca (AZN)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for AstraZeneca (AZN) from 2001 to 2025
| 2025 | $272.02B | $10.57B | 25.7× | -2.0× | |
| 2024 | $201.50B | $7.28B | 27.7× | -3.6× | |
| 2023 | $205.72B | $6.57B | 31.3× | +2.2× | |
| 2022 | $211.00B | $7.24B | 29.2× | -17.7× | |
| 2021 | $179.22B | $3.83B | 46.8× | -13.6× | |
| 2020 | $132.51B | $2.19B | 60.4× | -199.9× | |
| 2019 | $132.51B | $509.00M | 260.3× | +183.2× | |
| 2018 | $96.24B | $1.25B | 77.2× | +32.8× | |
| 2017 | $86.83B | $1.96B | 44.3× | +7.1× | |
| 2016 | $68.15B | $1.83B | 37.2× | -122.3× | |
| 2015 | $85.51B | $536.00M | 159.5× | +138.9× | |
| 2014 | $88.89B | $4.31B | 20.6× | +6.8× | |
| 2013 | $73.80B | $5.34B | 13.8× | -11.5× | |
| 2012 | $58.90B | $2.33B | 25.3× | +16.0× | |
| 2011 | $60.73B | $6.52B | 9.3× | +1.7× | |
| 2010 | $65.45B | $8.57B | 7.6× | -0.1× | |
| 2009 | $67.97B | $8.78B | 7.7× | -4.9× | |
| 2008 | $59.37B | $4.70B | 12.6× | +1.9× | |
| 2007 | $62.39B | $5.83B | 10.7× | -2.1× | |
| 2006 | $81.31B | $6.35B | 12.8× | -0.1× | |
| 2005 | $76.74B | $5.93B | 12.9× | -2.9× | |
| 2004 | $60.23B | $3.81B | 15.8× | -7.7× | |
| 2003 | $80.18B | $3.42B | 23.5× | +9.1× | |
| 2002 | $60.25B | $4.20B | 14.4× | -16.9× | |
| 2001 | $81.36B | $2.61B | 31.2× | — |
- 202525.7×
- 202427.7×
- 202331.3×
- 202229.2×
- 202146.8×
- 202060.4×
- 2019260.3×
- 201877.2×
- 201744.3×
- 201637.2×
- 2015159.5×
- 201420.6×
- 201313.8×
- 201225.3×
- 20119.3×
- 20107.6×
- 20097.7×
- 200812.6×
- 200710.7×
- 200612.8×
- 200512.9×
- 200415.8×
- 200323.5×
- 200214.4×
- 200131.2×
About P/FCF Ratio at AstraZeneca (AZN)
AstraZeneca (AZN) P/FCF ratio is 31.9× as of June 5, 2026. The 5-year average is 32.6×. The sector median currently stands at 19.8×. The current ratio is at the 47th percentile of its own 10-year history.
AstraZeneca (AZN) historical P/FCF ratio has ranged from a low of 6.7× (2011) to a high of 260.3× (2019) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
AstraZeneca P/FCF Ratio by Year
AstraZeneca P/FCF Ratio 2025: 25.7×
AstraZeneca (AZN) P/FCF ratio in 2025 was 25.7×, contracted from 27.7× the prior year.
AstraZeneca P/FCF Ratio 2024: 27.7×
AstraZeneca (AZN) P/FCF ratio in 2024 was 27.7×, contracted from 31.3× the prior year.
AstraZeneca P/FCF Ratio 2023: 31.3×
AstraZeneca (AZN) P/FCF ratio in 2023 was 31.3×, expanded from 29.2× the prior year.
AstraZeneca P/FCF Ratio 2022: 29.2×
AstraZeneca (AZN) P/FCF ratio in 2022 was 29.2×, contracted from 46.8× the prior year.
AstraZeneca P/FCF Ratio 2021: 46.8×
AstraZeneca (AZN) P/FCF ratio in 2021 was 46.8×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of AstraZeneca (AZN), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric